Efficacy and Hypoglycaemia Outcomes With Once-Weekly IcoSema Versus Comparators in Individuals With Type 2 Diabetes by Kidney and Liver Function: A Post Hoc Analysis of the COMBINE 1-3 Trials.

Diabetes Obes MetabAug 5, 2026 (epub)
Clinical ResearchEndocrinologyOpen access

Linong Ji, Jonas Dahl Andersen, Malik Benamar et al.

✦ AI-curated · Sources linked

In 30 seconds

This post hoc analysis of the COMBINE 1-3 trials evaluated the efficacy and hypoglycaemia outcomes of IcoSema in adults with type 2 diabetes, focusing on kidney and liver function subgroups. The study found no significant treatment interactions for HbA1c change or hypoglycaemia rates across subgroups, but significant interactions for achieving HbA1c <7.0% without weight gain in specific subgroups (p<0.05).

Key findings

  • No significant treatment interactions for HbA1c change or hypoglycaemia rates across kidney and liver function subgroups (all p>0.05).
  • Significant interactions for achieving HbA1c <7.0% without weight gain in kidney function subgroup in COMBINE 3 (p<0.05).
  • Significant treatment interactions for mean weekly total insulin dose in COMBINE 1 and 3 based on kidney function.

Why it matters

Understanding the efficacy and safety of diabetes treatments in patients with varying kidney and liver function is crucial for optimizing management strategies and minimizing hypoglycaemia risk in this population.

Source

PubMed · PMID 42557064Free full text on PubMed Central

Published in Diabetes Obes Metab. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Endocrinology

Clinical ResearchHematology

Ponatinib-Blinatumomab or Imatinib-Chemotherapy for Adult Ph-Positive ALL.

This multicenter, phase 3 randomized trial compared frontline ponatinib plus blinatumomab with imatinib plus chemotherapy in adults with Philadelphia-positive acute lymphoblastic leukemia.

N Engl J MedOct 15, 2026Read summary
Clinical ResearchHematology

Efficacy and safety of mitapivat in patients with sickle cell disease (RISE UP): a phase 3, double-blind, global, randomised, placebo-controlled trial.

RISE UP was a phase 3, double-blind, global, randomised, placebo-controlled trial conducted at 69 sites in 15 countries. It evaluated twice-daily mitapivat in patients older than 16 years with sickle cell disease…

LancetOct 24, 2026Read summary
Clinical ResearchRheumatology

Ianalumab for the Treatment of Patients with Sjögren's Disease.

Two 52-week, double-blind, randomized, placebo-controlled phase III trials evaluated monthly or less frequent ianalumab in patients with active Sjögren's disease.

N Engl J MedOct 22, 2026Read summary

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text
Create my personalized digestSee plans

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.